WILLOWBROOK, Ill. — September 14, 2026
Pharmazz, Inc. announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to sovateltide for the treatment of neonatal hypoxic-ischemic encephalopathy (NHIE). The designation represents a significant regulatory milestone for the company as it evaluates sovateltide as a potential treatment for a severe neonatal neurological condition associated with oxygen deprivation and restricted cerebral blood flow around birth. NHIE can result in acute neonatal mortality and long-term neurodevelopmental disabilities, including cerebral palsy, epilepsy and cognitive impairment, while therapeutic options remain limited. Pharmazz is developing sovateltide as a potential first-in-class therapy designed to address neurovascular injury through selective endothelin B receptor activation. The FDA orphan designation provides a development framework that can include incentives such as tax credits for qualified clinical testing, certain user-fee exemptions and potential U.S. market exclusivity following approval.
Sovateltide Targets Neurovascular Repair in NHIE
Sovateltide, also known as IRL-1620, is a selective endothelin-B receptor agonist designed to support biological processes involved in recovery following hypoxic and ischemic injury. Pharmazz states that the investigational therapy promotes neurogenesis, angiogenesis and neuronal survival, providing the mechanistic foundation for its potential use in conditions involving acute cerebral ischemia and hypoxia. In NHIE, reduced oxygen and blood flow around the time of birth can cause significant brain injury and may contribute to lasting neurological impairment. The company believes activation of the endothelin-B receptor pathway could support neural regeneration, neurovascular repair and neuroprotection in affected newborns. However, the NHIE program remains investigational, and further clinical development will be required to determine the safety and effectiveness of sovateltide specifically in this vulnerable patient population. The new FDA designation nevertheless strengthens Pharmazz’s regulatory position as it works toward advancing the program in communication with U.S. regulators..
Pharmazz Presents Broader Sovateltide Clinical Program
The FDA designation comes as Pharmazz prepares to present five sovateltide-related analyses and clinical development updates at the 18th World Stroke Congress, scheduled for October 21–23, 2026, in Seoul, South Korea. The presentations will cover a meta-analysis of sovateltide in acute ischemic stroke, the global Phase 3 RESPECT-ETB study, potential effects of sovateltide on the thrombolytic activity of alteplase and tenecteplase, an interim analysis from a multicenter randomized Phase 4 study, and the broader development of sovateltide for cerebral ischemic stroke. The RESPECT-ETB program is evaluating Tycamzzi® (sovateltide) in acute cerebral ischemic stroke across 57 sites in the United States, Germany, Spain and the United Kingdom, with a planned enrollment of 514 patients. These programs provide the broader clinical-development foundation for Pharmazz’s endothelin-B receptor strategy while the company evaluates opportunities to expand sovateltide into additional acute neurovascular conditions.
Advertisement
Pharmazz Expands Sovateltide Development Strategy
The orphan designation positions NHIE as an additional development opportunity for Pharmazz as the company builds a broader clinical strategy around sovateltide. The regulatory recognition may help support development of the therapy in a rare neonatal indication while the company continues its larger clinical programs in acute ischemic conditions. Pharmazz is focused on developing and commercializing first-in-class therapies for critical care and neurovascular diseases, with sovateltide representing its principal clinical-stage asset. The company’s near-term priorities include advancing the NHIE development program through regulatory discussions while generating additional clinical evidence through its ongoing stroke studies and upcoming scientific presentations. With FDA Orphan Drug Designation now secured for NHIE and multiple sovateltide programs progressing in ischemic stroke, Pharmazz is expanding the potential clinical scope of its endothelin-B receptor agonist platform across severe neurovascular conditions.
Source: Pharmazz, press release
